The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition

Blood

Volumn 113, Issue 13, 2009, Pages 3040-3049

  Bianchi, Giada ^a,b,c   Oliva, Laura ^a   Cascio, Paolo ^d   Pengo, Niccolò ^a,b   Fontana, Francesca ^a,b   Cerruti, Fulvia ^d   Orsi, Andrea ^a,b   Pasqualetto, Elena ^a   Mezghrani, Alexandre ^e   Calbi, Valeria ^a   Palladini, Giovanni ^f   Giuliani, Nicola ^g   Anderson, Kenneth C ^f   Sitia, Roberto ^a,b   Cenci, Simone ^a,b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF TURIN   (Italy)

^e CNRS   (France)

^f UNIVERSITY OF PAVIA   (Italy)

^g UNIVERSITY OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; BREFELDIN A; EPOXOMICIN; IMMUNOGLOBULIN; PROTEASOME; PROTEINASE INHIBITOR; THAPSIGARGIN; TUNICAMYCIN; UBIQUITIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; B LYMPHOCYTE DIFFERENTIATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG POTENTIATION; DRUG SENSITIVITY; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; UBIQUITINATION; WORKLOAD;

EID: 63849281664     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-08-172734     Document Type: Article

References (52)

1. KisselevAF, Goldberg AL. Proteasome inhibitors: from research tools to drug candidates. Chem Biol. 2001;8:739-758.
2. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer. 2002;2:175-187.
3. Adams J. The proteasome: a suitable antineo- plastic target. Nat Rev Cancer. 2004;4:349-360.
4. Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007;110:3557-3560.
5. Rajkumar SV, Richardson PG, HideshimaT Anderson KC. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol. 2005;23:630-639.
6. Richardson PG, Barlogie B, Berenson J, et al. Clinical factors predictive of outcome with bort- ezomib in patients with relapsed, refractory multiple myeloma. Blood. 2005;106:2977-2981.
7. Mulligan G, Mitsiades C, Bryant B, et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bort-ezomib. Blood. 2007;109:3177-3188.
8. Goldberg AL. Protein degradation and protection against misfolded or damaged proteins. Nature. 2003;426:895-899.
9. Glotzer M, Murray AW, Kirschner MW. Cyclin is degraded by the ubiquitin pathway. Nature. 1991; 349:132-138.
10. Zhao J, Tenev T, Martins LM, Downward J, Lemoine NR. The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle- dependent manner. J Cell Sci. 2000;113:4363-4371.
11. Anderson KC. Moving disease biology from the lab to the clinic. Cancer. 2003;97:796-801.
12. Yewdell JW, Reits E, Neefjes J. Making sense of mass destruction: quantitating MHC class I antigen presentation. Nat Rev Immunol. 2003;3:952-961.
13. Cenci S, Mezghrani A, Cascio P, et al. Progressively impaired proteasomal capacity during ter-minal plasma cell differentiation. EMBO J. 2006; 25:1104-1113.
14. Cascio P, Oliva L, Cerruti F, et al. Dampening Ab responses using proteasome inhibitors following in vivo B cell activation. Eur J Immunol. 2008;38: 658-667.
15. Neubert K, Meister S, Moser K, et al. The protea-some inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med. 2008;14:748-755.
16. Meister S, Schubert U, Neubert K, et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res. 2007;67:1783-1792.
17. Obeng EA, Carlson LM, Gutman DM, Harrington Jr WJ, Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood. 2006;107:4907-4916.
18. Markovina S, Callander NS, O'Connor SL, et al. Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells. Mol Cancer Res. 2008;6:1356-1364. 19. Wilson R, Freddi S, Chan D, Cheah KS, Bateman JF. Misfolding of collagen X chains harboring Schmid metaphyseal chondrodysplasiamuta-tions results in aberrant disulfide bond formation,intracellular retention, and activation of the unfolded protein response. J Biol Chem. 2005;280: 15544-15552.
19. Cascio P, Call M, Petre BM, Walz T, Goldberg AL. Properties of the hybrid form of the 26S protea-some containing both 19S and PA28 complexes. EMBO J. 2002;21:2636-2645.
20. Santoni de Sio FR, Cascio P, Zingale A, Gasparini M, Naldini L. Proteasome activity restricts lentiviral gene transfer into hematopoietic stem cells and is down-regulated by cytokines that enhance transduction. Blood. 2006;107: 4257-4265.
21. Cerruti F, Martano M, Petterino C, et al. Enhanced expression of interferon-gamma-induced antigen-processing machinery components in a spontaneously occurring cancer. Neoplasia. 2007;9:960-969.
22. Cascio P, Hilton C, Kisselev AF, Rock KL, Goldberg AL. 26S proteasomes and immunopro-teasomes produce mainly N-extended versions of an antigenic peptide. EMBO J. 2001;20:2357-2366.
23. Neefjes J, Dantuma NP. Fluorescent probes for proteolysis: tools for drug discovery. Nat Rev Drug Discov. 2004;3:58-69.
24. van Anken E, Romijn EP, Maggioni C, et al. Sequential waves of functionally related proteins are expressed when B cells prepare for antibody secretion. Immunity. 2003;18:243-253.
25. Goldberg AL, Cascio P, Saric T, Rock KL. The importance of the proteasome and subsequent proteolytic steps in the generation of antigenic peptides. Mol Immunol. 2002;39:147-164.
26. Schmidt M, Kloetzel PM. Biogenesis of eukaryotic 20S proteasomes: the complex maturation pathway of a complex enzyme. FASEB J. 1997;11: 1235-1243.
27. Eleuteri AM, Kohanski RA, Cardozo C, Orlowski M. Bovine spleen multicatalytic proteinase complex(proteasome): replacement of X, Y, and Z subunits by LMP7, LMP2, and MECL1 and changes in properties and specificity. J Biol Chem. 1997;272:11824-11831.
28. Noda C, Tanahashi N, Shimbara N, Hendil KB, Tanaka K. Tissue distribution of constitutive pro-teasomes, immunoproteasomes, and PA28 in rats. Biochem Biophys Res Commun. 2000;277: 348-354.
29. Dantuma NP, Lindsten K, Glas R, Jellne M,Masucci MG. Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells. Nat Biotech-nol. 2000;18:538-543.
30. Schroder M, Kaufman RJ. The mammalian unfolded protein response. Annu Rev Biochem. 2005;74:739-789.
31. Meiners S, Heyken D, Weller A, et al. Inhibition of proteasome activity induces concerted expression of proteasome genes and de novo formation of Mammalian proteasomes. J Biol Chem. 2003; 278:21517-21525.
32. Lundgren J, Masson P, Mirzaei Z, Young P. Identification and characterization of a Drosophila pro-teasome regulatory network. Mol Cell Biol. 2005; 25:4662-4675.
33. Hanna J, Finley D. A proteasome for all occasions. FEBS Lett. 2007;581:2854-2861.
34. Fuchs D, Berges C, Opelz G, Daniel V, Naujokat C. Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lym-phoma cells. J Cell Biochem. 2008;103:270-283.
35. Rutkowski DT, Kaufman RJ. That which does not kill me makes me stronger: adapting to chronic ER stress. Trends Biochem Sci. 2007;32:469-476.
36. Ma Y, Hendershot LM. The role of the unfolded protein response in tumour development: friend or foe? Nat Rev Cancer. 2004;4:966-977.
37. Mathew R, Karantza-Wadsworth V, White E. Role of autophagy in cancer. Nat Rev Cancer. 2007;7: 961-967.
38. Moenner M, Pluquet O, Bouchecareilh M, Chevet E. Integrated endoplasmic reticulum stress responses in cancer. Cancer Res. 2007;67:10631-10634.
39. Dang CV, Kim JW, Gao P, Yustein J. The interplay between MYC and HIF in cancer. Nat Rev Cancer. 2008;8:51-56.
40. Reimold AM, Iwakoshi NN, Manis J, et al. Plasma cell differentiation requires the transcription factor XBP-1. Nature. 2001;412:300-307.
41. Iwakoshi NN, Lee AH, Vallabhajosyula P, Otipoby KL, Rajewsky K, Glimcher LH. Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1. Nat Immunol. 2003;4:321-329.
42. Nakamura M, Gotoh T, Okuno Y, et al. Activation of the endoplasmic reticulum stress pathwayis associated with survival of myeloma cells. Leuk Lymphoma. 2006;47:531-539.
43. Carrasco DR, Sukhdeo K, Protopopova M, et al. The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell. 2007;11:349-360.
44. Lee AH, Iwakoshi NN, Anderson KC, Glimcher LH. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci U S A. 2003;100:9946-9951.
45. Wu J, Kaufman RJ. From acute ER stress to physiological roles of the Unfolded Protein Response. Cell Death Differ. 2006;13:374-384.
46. Boyce M, Yuan J. Cellular response to endoplas-mic reticulum stress: a matter of life or death. Cell Death Differ. 2006;13:363-373.
47. Davenport EL, Moore HE, Dunlop AS, et al. Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells. Blood. 2007;110:2641-2649.
48. Gu H, Chen X, Gao G, Dong H. Caspase-2 functions upstream of mitochondria in endoplasmic reticulum stress-induced apoptosis by bortezomib in human myeloma cells. Mol Cancer Ther. 2008; 7:2298-2307.
49. Busse A, Kraus M, Na IK, et al. Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of protea-some subunits. Cancer. 2008;112:659-670.
50. Chondrogianni N, Tzavelas C, Pemberton AJ, Nezis IP, Rivett AJ, Gonos ES. Overexpression of proteasome beta5 assembled subunit increases the amount of proteasome and confers ameliorated response to oxidative stress and higher survival rates. J Biol Chem. 2005;280:11840-11850.
51. Oerlemans R, Franke NE, Assaraf YG, et al. Molecular basis of bortezomib resistance: protea-some subunit beta5(PSMB5) gene mutation and overexpression of PSMB5 protein. Blood. 2008; 112:2489-2499.
52. Manz RA, Hauser AE, Hiepe F, Radbruch A. Maintenance of serum antibody levels. Annu Rev Immunol. 2005;23:367-386.